INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Oct 22, 2026

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived for approximately 90 days. The conferen.

Business Wire • Oct 21, 2026

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.

Zacks Investment Research • Oct 13, 2026

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

Zacks Investment Research • Oct 9, 2026

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041

ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.

Zacks Investment Research • Sep 29, 2026

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled “Methods and Compositions for Treatment of Rett Syndrome.” The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrative.

Business Wire • Sep 28, 2026

3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI

Options bears are circling three stocks today, with Aemetis Inc (NASDAQ:AMTX), Acadia Pharmaceuticals Inc (NASDAQ:ACAD), and Resideo Technologies Inc (NYSE:REZI) all seeing puts handily outpace calls.

Schaeffers Research • Sep 28, 2026

ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal

Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.

Zacks Investment Research • Sep 25, 2026

Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study

Acadia Pharmaceuticals said on Thursday its experimental drug for psychosis associated with Alzheimer's missed the main goal of ​a mid-stage study testing whether it could reduce hallucinations ‌and delusions in patients with the condition.

Reuters • Sep 24, 2026

Bears Chase Down Acadia Pharma After Surprise Alzheimer's Setback

Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark in a Phase 2 study.

Investors Business Daily • Sep 24, 2026